Inflarx N.V. ((IFRX)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
InflaRx N.V. is conducting a Phase 2a open-label basket study to evaluate the safety and pharmacokinetics of INF904, an oral C5aR1 inhibitor, in patients with moderate to severe chronic spontaneous urticaria or hidradenitis suppurativa. This study aims to assess the drug’s safety profile and how it is processed in the body, which is crucial for advancing treatment options for these conditions.
The study tests various doses of INF904, targeting different patient groups based on their response to treatment. The drug is administered orally, with the goal of reducing symptoms associated with the conditions.
The study is randomized with a parallel intervention model, meaning participants are assigned to different treatment groups. There is no masking, as all participants and researchers are aware of the treatment being administered. The primary purpose is treatment-focused.
The study began on August 7, 2024, with a primary completion date yet to be announced. The latest update was submitted on August 19, 2025. These dates are important as they indicate the study’s progress and potential timeline for results.
This study update could influence InflaRx’s stock performance, as positive results may boost investor confidence. The pharmaceutical industry is highly competitive, and advancements in treatment options can significantly impact market dynamics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.